Virtu KCG Holdings LLC Takes Position in Aerie Pharmaceuticals, Inc. (AERI)

Virtu KCG Holdings LLC purchased a new position in shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,412 shares of the company’s stock, valued at approximately $284,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. bought a new position in shares of Aerie Pharmaceuticals during the first quarter worth about $108,000. BNP Paribas Arbitrage SA grew its position in shares of Aerie Pharmaceuticals by 2,711.4% during the second quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after acquiring an additional 3,579 shares during the last quarter. BlueCrest Capital Management Ltd bought a new position in shares of Aerie Pharmaceuticals during the first quarter worth about $202,000. Amalgamated Bank bought a new position in shares of Aerie Pharmaceuticals during the second quarter worth about $204,000. Finally, Palisade Capital Management LLC NJ bought a new position in shares of Aerie Pharmaceuticals during the second quarter worth about $212,000. Institutional investors and hedge funds own 94.64% of the company’s stock.

Several equities analysts have recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $62.00 price target (up previously from $56.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, July 20th. Canaccord Genuity restated a “positive” rating and set a $73.00 price target (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Mizuho restated a “buy” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. BidaskClub upgraded shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $76.00 price target (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $68.92.

TRADEMARK VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2017/10/21/virtu-kcg-holdings-llc-takes-position-in-aerie-pharmaceuticals-inc-aeri.html.

Shares of Aerie Pharmaceuticals, Inc. (AERI) opened at 65.10 on Friday. The firm has a 50-day moving average of $56.74 and a 200-day moving average of $51.50. Aerie Pharmaceuticals, Inc. has a one year low of $32.05 and a one year high of $66.10. The firm’s market capitalization is $2.37 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.02. On average, equities analysts predict that Aerie Pharmaceuticals, Inc. will post ($2.59) earnings per share for the current fiscal year.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye.

Other institutional investors have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. bought a new position in shares of Aerie Pharmaceuticals during the first quarter worth about $108,000. BNP Paribas Arbitrage SA grew its position in shares of Aerie Pharmaceuticals by 2,711.4% during the second quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after acquiring an additional 3,579 shares during the last quarter. BlueCrest Capital Management Ltd bought a new position in shares of Aerie Pharmaceuticals during the first quarter worth about $202,000. Amalgamated Bank bought a new position in shares of Aerie Pharmaceuticals during the second quarter worth about $204,000. Finally, Palisade Capital Management LLC NJ bought a new position in shares of Aerie Pharmaceuticals during the second quarter worth about $212,000. Institutional investors and hedge funds own 94.64% of the company’s stock.

Several equities analysts have recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $62.00 price target (up previously from $56.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, July 20th. Canaccord Genuity restated a “positive” rating and set a $73.00 price target (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Mizuho restated a “buy” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. BidaskClub upgraded shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $76.00 price target (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $68.92.

TRADEMARK VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2017/10/21/virtu-kcg-holdings-llc-takes-position-in-aerie-pharmaceuticals-inc-aeri.html.

Shares of Aerie Pharmaceuticals, Inc. (AERI) opened at 65.10 on Friday. The firm has a 50-day moving average of $56.74 and a 200-day moving average of $51.50. Aerie Pharmaceuticals, Inc. has a one year low of $32.05 and a one year high of $66.10. The firm’s market capitalization is $2.37 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.02. On average, equities analysts predict that Aerie Pharmaceuticals, Inc. will post ($2.59) earnings per share for the current fiscal year.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply